Study Evaluation LXR-623 in Healthy Adults

Phase 1

Terminated

• Conditions: Healthy Subjects

• Registration Number: NCT00379860
• Lead Sponsor: Wyeth is now a wholly owned subsidiary of Pfizer

Brief Summary

To evaluate the safety and tolerability of multiple doses of LXR in healthy adults.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2006-09-21
• Study First Submitted QC: 2006-09-21
• Study First Posted: 2006-09-25
• Study Start: 2006-10
• Study Completion: 2007-01
• Status Verified: 2007-03
• Last Update Submitted: 2007-03-08
• Last Update Posted: 2007-03-09

Recruitment & Eligibility

• Status: TERMINATED
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Generally healthy adults.
• Liver function tests, triglycerideres, and creatinine must be below upper limit of normal at screening.

Exclusion Criteria

• A history or active presence of clinically important medical disease.
• Any metal implants or devices.
• Claustrophobia.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Primary Outcome Measures

Name	Time	Method
Safety is the primary outcome.